Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Prichard BNC et al.  
Dose Relation of Blood Pressure Reduction with Moxonidine: Findings from Three Placebo- and Active-Controlled Randomized Studies

Journal of Clinical and Basic Cardiology 2003; 6 (1-4): 49-51

PDF    Summary    Figures   

Fig. 1: Hypertonie - Moxonidin

Keywords: BlutdruckcardiologyhypertensionKardiologieMoxonidinmoxonidineStudiestudies

Three placebo-controlled trials based on a standardized protocol and methodology have compared the blood pressure-lowering effect of once-daily moxonidine with that of the angiotensin-converting enzyme (ACE) inhibitor enalapril. Data from these studies were used to examine the dose-relation of blood pressure responses to moxonidine. Combined analysis of these studies (n = 461), based on intention-to-treat analysis of placebo-corrected mean changes in office sitting diastolic blood pressure (SiDBP) at trough, revealed that moxonidine produced a progressive, dose-proportionate blood pressure-lowering effect across its recommended dose range (0.2-0.6 mg/day). This evidence for a dose-dependent blood pressure-lowering effect of moxonidine was confirmed by 24-hour ambulatory blood pressure recordings (ABPM). Placebo-adjusted mean changes in SiDBP during ABPM were -4.8, -9.4 and -10.3 mmHg, respectively, with moxonidine 0.2, 0.4 and 0.6 mg/day (p < 0.001 for comparison of each dose versus placebo). In all three studies enalapril reduced blood pressure significantly more than placebo and showed equivalence with moxonidine. We conclude that single daily doses of moxonidine in the range 0.2-0.6 mg produce dose-dependent, clinically relevant and statistically significant decreases in SiDBP at trough.
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum